Compare TNXP & BZUN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNXP | BZUN |
|---|---|---|
| Founded | 2007 | 2007 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Catalog/Specialty Distribution |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.7M | 164.5M |
| IPO Year | 2008 | 2014 |
| Metric | TNXP | BZUN |
|---|---|---|
| Price | $13.47 | $2.81 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 425.9K | 186.5K |
| Earning Date | 05-11-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.75 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,107,000.00 | N/A |
| Revenue This Year | $558.11 | $7.89 |
| Revenue Next Year | $38.29 | $6.16 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 29.85 | N/A |
| 52 Week Low | $9.40 | $2.07 |
| 52 Week High | $34.00 | $4.88 |
| Indicator | TNXP | BZUN |
|---|---|---|
| Relative Strength Index (RSI) | 59.03 | 49.53 |
| Support Level | $11.98 | $2.61 |
| Resistance Level | $13.36 | $2.82 |
| Average True Range (ATR) | 0.79 | 0.10 |
| MACD | 0.09 | -0.01 |
| Stochastic Oscillator | 60.55 | 29.25 |
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
Baozun Inc is engaged to provide its customers with end-to-end e-commerce solutions including the sales of apparel, home and electronic products, online store design and setup, visual merchandising and marketing, online store operations, customer services, warehousing and order fulfillment, as well as the holistic brand management, including tactic positioning, branding and marketing, retail and e-commerce operations, supply chain and logistics, and technology empowerment. It has two operating segments: E-Commerce (encompassing BEC and BZI) and Brand Management (representing BBM). The company generates maximum of its revenue from E-Commerce (encompassing BEC and BZI) segment.